| pubmed-article:1525605 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1525605 | lifeskim:mentions | umls-concept:C0026809 | lld:lifeskim |
| pubmed-article:1525605 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:1525605 | pubmed:dateCreated | 1992-10-22 | lld:pubmed |
| pubmed-article:1525605 | pubmed:abstractText | Despite major advances, graft-versus-host disease (GVHD) remains a major obstacle to clinical bone marrow transplantation. Prophylaxis by T cell depletion is associated with increased rates of engraftment failure and leukemic relapse. Treatment with high-dose IL-2 can markedly protect lethally irradiated mice from GVHD-related mortality, especially when T cell-depleted (TCD) syngeneic bone marrow cells (BMC) are co-administered. In these IL-2-protected animals, allogeneic reconstitution is observed, and a graft-versus-leukemia effect of allogeneic T cells is preserved. To determine whether IL-2 might increase alloresistance under conditions in which alloengraftment is more difficult to achieve, we have now evaluated the possible effect of IL-2 on: (1) competitive repopulation of lethally irradiated mice by mixtures of TCD allogeneic and TCD syngeneic BMC; (2) radiation protection by TCD allogeneic BMC; (3) timing of hematologic recovery; and (4) allogeneic engraftment in sublethally irradiated recipients. The results show that IL-2 has only a limited and strain-restricted effect on alloengraftment. This effect may reflect activation of alloresistant host natural killer cells, a cell population which is not essential for the protective effect of IL-2 against GVHD. | lld:pubmed |
| pubmed-article:1525605 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1525605 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1525605 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1525605 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1525605 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1525605 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1525605 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:1525605 | pubmed:issn | 0268-3369 | lld:pubmed |
| pubmed-article:1525605 | pubmed:author | pubmed-author:SykesMM | lld:pubmed |
| pubmed-article:1525605 | pubmed:author | pubmed-author:PearsonD ADA | lld:pubmed |
| pubmed-article:1525605 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1525605 | pubmed:volume | 10 | lld:pubmed |
| pubmed-article:1525605 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1525605 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1525605 | pubmed:pagination | 157-63 | lld:pubmed |
| pubmed-article:1525605 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:1525605 | pubmed:meshHeading | pubmed-meshheading:1525605-... | lld:pubmed |
| pubmed-article:1525605 | pubmed:meshHeading | pubmed-meshheading:1525605-... | lld:pubmed |
| pubmed-article:1525605 | pubmed:meshHeading | pubmed-meshheading:1525605-... | lld:pubmed |
| pubmed-article:1525605 | pubmed:meshHeading | pubmed-meshheading:1525605-... | lld:pubmed |
| pubmed-article:1525605 | pubmed:meshHeading | pubmed-meshheading:1525605-... | lld:pubmed |
| pubmed-article:1525605 | pubmed:meshHeading | pubmed-meshheading:1525605-... | lld:pubmed |
| pubmed-article:1525605 | pubmed:meshHeading | pubmed-meshheading:1525605-... | lld:pubmed |
| pubmed-article:1525605 | pubmed:meshHeading | pubmed-meshheading:1525605-... | lld:pubmed |
| pubmed-article:1525605 | pubmed:meshHeading | pubmed-meshheading:1525605-... | lld:pubmed |
| pubmed-article:1525605 | pubmed:meshHeading | pubmed-meshheading:1525605-... | lld:pubmed |
| pubmed-article:1525605 | pubmed:meshHeading | pubmed-meshheading:1525605-... | lld:pubmed |
| pubmed-article:1525605 | pubmed:year | 1992 | lld:pubmed |
| pubmed-article:1525605 | pubmed:articleTitle | Alloengraftment in IL-2-treated mice. | lld:pubmed |
| pubmed-article:1525605 | pubmed:affiliation | Transplantation Biology Research Center, Massachusetts General Hospital, Harvard Medical School, Charlestown 02129. | lld:pubmed |
| pubmed-article:1525605 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1525605 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:1525605 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
